首頁 > 市場調查報告書 > 製藥

糖尿病

市場調查報告書

商品編碼

1620344

全球糖尿病潰瘍治療市場規模：按治療、按類型、按最終用戶、按地區、範圍和預測

Global Diabetic Ulcers Treatment Market Size By Treatment (Wound Care Dressings, Wound Care Devices), By Type (Foot Ulcer, Mouth Ulcer), By End-User (Hospitals And Clinics, Ambulatory Surgical Centers), By Geographic Scope And Forecast

出版日期: 2024年07月26日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

糖尿病潰瘍治療的市場規模與預測

2023年糖尿病潰瘍治療市場規模為91.7億美元，預計2024年至2031年複合年增長率為5.40%，到2031年將達到134.4億美元。糖尿病潰瘍是一種主要發生在糖尿病患者的足部和小腿上的慢性傷口。這些潰瘍是由於周圍神經病變和血液交叉不良等問題而形成的，從而降低了身體癒合傷口的能力。糖尿病潰瘍的治療採用多學科策略，包括傷口護理、感染控制、血糖控制、傷口敷料、擦傷和生長因子等先進治療。在嚴重的情況下，可能需要手術介入或高壓氧治療來加速康復並避免截肢等併發症。

隨著全球糖尿病盛行率的不斷上升，對高效糖尿病潰瘍治療的需求將急劇增加。生物技術和再生醫學的進步正在推動該領域的創新，包括生物工程皮膚替代品、幹細胞療法和創新的傷口癒合劑。

遠距醫療和人工智慧在傷口護理管理中的整合有可能透過實現遠端監控和個人化治療策略來改善患者的治療結果。隨著醫療保健系統轉向預防措施和早期幹預，糖尿病潰瘍治療市場預計將擴大，特別是在亞太地區和北美等糖尿病人口不斷增長的地區。

糖尿病潰瘍治療的全球市場動態

塑造全球糖尿病潰瘍治療市場的關鍵市場動態

主要市場驅動因子

糖尿病盛行率增加：

根據國際糖尿病聯盟的數據，預計 2021 年全球糖尿病患者人數將達到約 5.37 億，2045 年將達到 7.83 億。這種增長推動了對糖尿病潰瘍治療的需求，因為糖尿病會損害傷口癒合，導致更頻繁的慢性潰瘍以及感染和截肢等相關問題。隨著糖尿病人口的增長，對降低風險並改善患者預後的有效傷口治療的需求也在增加。

人口老化加劇：

世界衛生組織 (WHO) 預測，60 歲以上人口數量將從 2020 年的 10 億增加到 2030 年的 14 億。由於與年齡相關的循環和免疫功能的變化，糖尿病及其後果、傷口癒合不良和糖尿病潰瘍在老年人中更為常見。隨著人口老化的增加，對有效潰瘍治療解決方案的需求將會增加，以解決該年齡層慢性傷口風險增加和相關後果的問題。

醫療支出增加：

醫療保健支出的增加，尤其是在新興國家，正在推動糖尿病潰瘍治療市場的發展。根據世界銀行數據，全球衛生支出佔GDP的比重從2000年的9.2%上升到2018年的9.8%。支出的增加將使人們能夠更多地獲得創新治療、更強大的醫療保健基礎設施以及更好的傷口護理管理。隨著衛生預算的擴大，更多的資源被投入到慢性病管理，例如糖尿病潰瘍治療，並且患者獲得專門和新穎治療的機會正在改善。

主要問題

感染風險高：

糖尿病潰瘍感染的風險很高，這會使治療複雜化並延遲康復。日益嚴重的抗生素抗藥性問題也加劇了這個問題，使得適當管理傳染病變得困難。這延長了治療的持續時間和成本，限制了現有藥物的有效性和市場成長。

先進療法的監管障礙：

幹細胞、基因療法和生物人造皮膚等先進藥物需要嚴格的監管批准。漫長而昂貴的審批流程阻礙了新療法向市場的推出。監管障礙阻止患者獲得可能挽救生命的治療方法並限制市場成長。

治療費用高：

對許多患者來說，晚期糖尿病潰瘍的治療費用（包括生物工程皮膚替代品和幹細胞治療）可能太高，尤其是在欠發達國家。由於醫療保健系統和患者難以負擔治療費用，如此高的治療成本限制了接受度並影響了整體市場成長。

癒合過程緩慢：

由於血液循環不良和血糖水平較高，糖尿病潰瘍通常癒合緩慢。治癒率的延遲會增加治療時間和成本，給醫療保健系統帶來進一步的壓力，限制有效治療解決方案的可擴展性，並阻礙市場成長。

主要趨勢：

傷口處理技術的進步：

生物工程皮膚替代品、生長激素和幹細胞療法等傷口治療技術的進步將提高治療糖尿病潰瘍的效率。這些技術可加速癒合、降低感染風險並改善患者治療效果，隨著越來越多的醫療保健專業人員使用先進的傷口照護系統，市場將會擴大。

遠距醫療的普及：

遠距醫療在糖尿病潰瘍治療中越來越受歡迎，因為它允許遠端監控患者和評估傷口。這種趨勢對於居住在偏遠地區或無法經常去醫院就診的患者尤其有利。遠距醫療因其便利性和可近性而被採用，提高了患者的依從性並允許早期幹預。

將人工智慧 (AI) 融入傷口護理：

人工智慧 (AI) 越來越多地應用於糖尿病潰瘍管理，以幫助醫療保健臨床醫生預測傷口癒合結果、追蹤治療進度並推薦量身定制的治療策略，我正在這樣做。人工智慧提高了診斷準確性和治療效果，透過增強整體患者護理和簡化治療方法來推動市場成長。

Diabetic Ulcers Treatment Market size was valued at USD 9.17 Billion in 2023 and is projected to reach USD 13.44 Billion by 2031, growing at a CAGR of 5.40% from 2024 to 2031. Diabetic ulcers are chronic wounds that primarily affect the feet and lower extremities of diabetics. These ulcers form as a result of issues such as peripheral neuropathy and poor circulation, which reduce the body's capacity to heal wounds properly. Diabetic ulcers are treated using a multidisciplinary strategy that includes wound care, infection control, glucose management, and advanced therapies such as wound dressings, debridement, and growth factors. In severe situations, surgical intervention or hyperbaric oxygen therapy may be necessary to promote recovery and avoid complications such as amputation.

The increased prevalence of diabetes globally, the demand for efficient diabetic ulcer therapies is likely to increase dramatically. Biotechnology and regenerative medicine advancements are driving innovation in the field, including bioengineered skin substitutes, stem cell therapies, and innovative wound healing agents.

The integration of telemedicine and artificial intelligence in wound care management has the potential to improve patient outcomes by allowing for remote monitoring and individualized treatment strategies. As healthcare systems shift toward preventative measures and early interventions, the market for diabetic ulcer therapy is expected to grow, particularly in regions with growing diabetes populations, such as Asia-Pacific and North America.

Global Diabetic Ulcers Treatment Market Dynamics

The key market dynamics that are shaping the global diabetic ulcers treatment market include:

Key Market Drivers:

Increasing Prevalence of Diabetes:

The rising incidence of diabetes is a primary driver of the diabetic ulcer treatment market, with roughly 537 million adults affected globally in 2021 and a predicted 783 million by 2045, according to the International Diabetes Federation. This increase has driven up demand for diabetic ulcer treatments since diabetes hinders wound healing, resulting in a higher frequency of chronic ulcers and associated problems such as infections and amputations. As the diabetes population expands, so will the demand for effective wound care treatments to mitigate risks and enhance patient outcomes.

Growing Aging Population:

The growing aging population is a major driver of the diabetic ulcer treatment market, with the World Health Organization predicting that the number of individuals aged 60 and over will increase from 1 billion in 2020 to 1.4 billion by 2030. Diabetes and its consequences, such as poor wound healing and diabetic ulcers, are more common in older persons due to changes in circulation and immunological function caused by aging. As the older population grows, the demand for efficient ulcer treatment solutions will rise to meet the increased risk of chronic wounds and accompanying consequences in this age range.

Increasing Healthcare Expenditure:

Increasing healthcare expenditure, particularly in emerging nations, is propelling the diabetic ulcer treatment market. According to World Bank data, global health expenditure as a proportion of GDP increased from 9.2% in 2000 to 9.8% in 2018. This increased spending enables greater access to innovative treatments, enhanced healthcare infrastructure, and better wound care management. As healthcare budgets expand, more resources are directed into chronic disease management, such as diabetic ulcer treatments, improving patient access to specialized care and novel therapies.

Key Challenges:

High Risk of Infection:

Diabetes ulcers have a high risk of infection, which can complicate therapy and slow recovery. The growing issue of antibiotic resistance exacerbates this problem, making it difficult to properly manage infections. This lengthens treatment times and expenses, restricting the efficacy of current medicines and market growth.

Regulatory Barriers for Advanced Therapies:

Advanced medicines such as stem cells, gene therapy, and bioengineered skin substitutes are subject to demanding regulatory approval. Long and expensive approval processes impede the introduction of novel treatments to the market. Regulatory hurdles impede patient access to potentially life-saving treatments, limiting market growth.

High Treatment Costs:

Treatment costs for advanced diabetic ulcers, including bioengineered skin substitutes and stem cell therapies, might be too expensive for many patients, particularly in underdeveloped nations. The high cost of these treatments limits acceptance and has an impact on overall market growth, as healthcare systems and patients struggle to afford them.

Slow Healing Process:

Diabetic ulcers typically heal slowly due to poor circulation and high blood sugar levels. The delayed rate of healing increases the length and cost of care, putting additional strain on healthcare systems and restricting the scalability of effective treatment solutions, stifling market growth.

Key Trends:

Advances in Wound Care Technologies:

Advances in wound care technology, including bioengineered skin substitutes, growth hormones, and stem cell therapies, enhance the efficiency of diabetic ulcer treatments. These technologies promote faster healing, lower infection risks, and improve patient outcomes, resulting in market development as more healthcare providers use advanced wound treatment systems.

Increasing Adoption of Telemedicine:

Telemedicine is gaining traction in diabetic ulcer treatment as it allows for remote patient monitoring and wound assessment. This trend is especially advantageous for patients who live in remote areas or are unable to travel frequently to the clinic. Telemedicine is being adopted due to its convenience and accessibility, which improves patient compliance and allows for early intervention.

Integration of Artificial Intelligence (AI) in Wound Care:

Artificial Intelligence (AI) is increasingly being used in diabetic ulcer management, assisting healthcare clinicians in predicting wound healing outcomes, tracking treatment progress, and recommending tailored care strategies. AI improves diagnostic accuracy and treatment efficacy, resulting in market growth by enhancing overall patient care and streamlining treatment methods.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Diabetic Ulcers Treatment Market Regional Analysis

Here is a more detailed regional analysis of the global diabetic ulcers treatment market:

North America:

North America currently dominates the global diabetic ulcer treatment market, which is projected to continue in the coming years. One of the primary factors is the high incidence of diabetes in the region, with the Centers for Disease Control and Prevention (CDC) claiming that 37.3 million Americans, or 11.3% of the population, had diabetes in 2021. This figure is expected to increase rapidly, reaching 60.6 million by 2060.

The region has a higher-than-average incidence of diabetic foot ulcers, with a 2022 study in the Journal of the American Medical Association (JAMA) indicating an annual rate of 2.2%, which is projected to rise to 2.5% by 2030. These causes, combined with an aging population, increase the patient pool as older persons are more susceptible to diabetes and accompanying problems.

North America's strong healthcare infrastructure and significant research investments are also driving market expansion. In 2020, the National Institutes of Health (NIH) will invest USD 1.15 Billion in diabetes research, promoting innovation in therapies for diabetic complications such as ulcers. Rising healthcare spending in the United States, expected to reach USD 6.2 Trillion by 2028, supports further investment in advanced ulcer therapies. These characteristics, together with a growing older population and continuing advances in medical technology, are driving North America's leadership in the diabetic ulcer treatment market.

Asia Pacific:

The Asia Pacific region's fastest-growing to the top of the list for diabetic ulcer treatment markets. One of the key factors is the region's increasing prevalence of diabetes, notably in China and India. According to the International Diabetes Federation's (IDF) Diabetes Atlas 2021, the Western Pacific area had 206 million adults with diabetes in 2021, with the amount expected to climb to 260 million by 2045. This increase dramatically raises the number of individuals at risk of acquiring diabetic complications including foot ulcers, which currently afflict millions.

Furthermore, increased healthcare expenditure and improved healthcare infrastructure are important drivers driving market expansion. According to the World Health Organization (WHO), health spending in the Asia Pacific region has grown at an average annual rate of 6.7%, outperforming economic development, while countries such as China seek to expand healthcare spending to 7% of GDP by 2030. The region's vast and aging population also plays an important role, with the number of persons aged 60 and up predicted to more than double by 2050. This demographic shift, together with increased knowledge of diabetic complications and improved healthcare access, positions the Asia-Pacific area as an essential market for diabetic ulcer therapy in the coming years.

Global Diabetic Ulcers Treatment Market: Segmentation Analysis

The Global Diabetic Ulcers Treatment Market is Segmented on the basis of Treatment, Type, End-User, And Geography.

Diabetic Ulcers Treatment Market, By Treatment

Wound Care Dressings
Wound Care Devices
Active Therapies

Based on Treatment, the market is bifurcated into Wound Care Dressings, Wound Care Devices, and Active Therapies. Wound care dressings dominate as they are widely used to treat a variety of ulcers, including diabetic foot ulcers. Hydrocolloid, foam, and antimicrobial dressings serve to keep the healing environment wet, lower the risk of infection, and promote faster recovery. Active therapies are the fastest-growing area, due to advances in bioengineered skin substitutes, growth factors, and stem cell therapies, which provide more effective options for difficult-to-heal diabetic ulcers, especially in cases when conventional treatments are ineffective.

Diabetic Ulcers Treatment Market, By Type

Foot Ulcer
Mouth Ulcer
Skin Ulcer

Based on Type, the market is segmented into Foot Ulcer, Mouth Ulcer, and Skin Ulcer. The foot ulcer segment is currently dominant due to the high frequency of diabetic foot ulcers among diabetics, which is exacerbated by variables such as neuropathy and poor circulation, all of which increase the risk of foot injuries and infections. The mouth ulcer segment is expanding at a rapid pace, owing to increased knowledge and better diagnostic procedures for diabetic oral complications, as well as an increase in lifestyle-related variables contributing to oral health problems. This development reflects a larger recognition of the need to address all types of ulcers in diabetes individuals in order to enhance overall health.

Diabetic Ulcers Treatment Market, By End-User

Hospitals And Clinics
Ambulatory Surgical Centers
Academic and Research Organizations

Based on End-User, the market is segmented into Hospitals and Clinics, Ambulatory Surgical Centers, and Academic and Research Organizations. Hospitals and clinics dominate the market, owing to their extensive healthcare offerings, superior wound care facilities, and access to specialized medical professionals capable of effectively managing severe diabetic ulcer patients. This component is essential for providing inpatient and outpatient care, guaranteeing a comprehensive approach to treatment. Ambulatory surgery facilities are the fastest-growing group, driven by an increasing desire for outpatient operations, cost-effectiveness, and a growing demand for minimally invasive therapies. These centers are becoming increasingly popular for wound management and ulcer surgery, indicating a shift toward more accessible and efficient patient care.

Key Players

The "Global Diabetic Ulcers Treatment Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
ConvaTec Group Plc, Smith & Nephew Plc, 3M Company, Coloplast AS, B. Braun SE, Medline Industries LP, MiMedx Group, Inc., Organogenesis Inc., URGO Medical, Healthium Medtech, Molnlycke Healthcare, Paul Hartmann AG, and Systagenix Wound Management.
The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Diabetic Ulcers Treatment Market Recent Developments
In April 2023, 3M Health Care's revolutionary 3M Veraflo therapy, which includes both 3M Veraflo cleanse choice complete dressing and 3M V.A.C. Veraflo cleanse choice dressing, obtained FDA approval for the hydromechanical removal of infectious materials, non-viable tissue, and wound debris. This enabled the company to expand its treatment type offers and launch new treatment types into the market.
In June 2022, Smith & Nephew will launch a new R&D and manufacturing facility in Hull, UK, for its advanced wound treatment franchise. This strategy enabled the corporation to expand its research operations and enhance its production capacity

1 INTRODUCTION OF GLOBAL DIABETIC ULCERS TREATMENT MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL DIABETIC ULCERS TREATMENT MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY TREATMENT

5.1 Overview
5.2 Wound Care Dressings
5.3 Wound Care Devices
5.4 Active Therapies

6 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY TYPE

6.1 Overview
6.2 Foot Ulcer
6.3 Mouth Ulcer
6.4 Skin Ulcer

7 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY END-USER

7.1 Overview
7.2 Hospitals and Clinics
7.3 Ambulatory Surgical Centers
7.4 Academic and Research Organizations

8 GLOBAL DIABETIC ULCERS TREATMENT MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL DIABETIC ULCERS TREATMENT MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies

10 COMPANY PROFILES

10.1 ConvaTec Group Plc
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Smith & Nephew Plc
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 3M Company
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Molnlycke Health Care AB
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Coloplast AS
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 B. Braun SE
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Medline Industries LP
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 MiMedx Group Inc.
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Organogenesis Inc.
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 URGO Medical
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments